Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prednisone

FDA-approved product (tablet, oral), marketed as Cortan, Delta-Dome, Deltasone and 10 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Prednisone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenal gland disease
  • Allergic conjunctivitis
  • Allergic rhinitis
  • Anemia
  • Ankylosing spondylitis
  • Aplastic anemia
  • Arthritis
  • Asthma
  • Atopic eczema
  • Autoimmune thrombocytopenic purpura
  • Berylliosis
  • Brain neoplasm
  • Bursitis
  • Cancer
  • Chorioretinitis
  • Choroiditis
  • and 60 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids acting locally; Corticosteroids; Corticosteroids, weak (group i); Corticosteroids, weak, other combinations
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prednisone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prednisone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

    NCT01309789 · start 2011-02

    Registered record
    Registry ID
    NCT01309789
    Conditions
    Lymphoma, Large-Cell, Anaplastic; Lymphoma, NK-cell; Lymphoma, T-cell
    Interventions
    brentuximab vedotin; cyclophosphamide; brentuximab vedotin; prednisone; cyclophosphamide; doxorubicin; doxorubicin; prednisone; vincristine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-02
    Completion
    2017-02-28
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Large-Cell, Anaplastic; Lymphoma, NK-cell; Lymphoma, T-cell
    Interventionbrentuximab vedotin; cyclophosphamide; brentuximab vedotin; prednisone +5 more
    PhasePhase 1
    Registry statusCompleted

  • Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

    NCT01254279 · start 2010-12

    Registered record
    Registry ID
    NCT01254279
    Conditions
    Prostate Cancer Metastatic
    Interventions
    CABAZITAXEL
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-12
    Completion
    2014-12
    Enrolment
    984

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionCABAZITAXEL
    PhasePhase 3
    Registry statusCompleted

  • Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate

    NCT01199029 · start 2010-08

    Registered record
    Registry ID
    NCT01199029
    Conditions
    Healthy
    Interventions
    PF-04308515; PF-04308515; Prednisone; PF-04308515; PF-04308515; Prednisone; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    2010-09
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-04308515; PF-04308515; Prednisone; PF-04308515 +3 more
    PhasePhase 1
    Registry statusCompleted

  • Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

    NCT01154387 · start 2010-07

    Registered record
    Registry ID
    NCT01154387
    Conditions
    End Stage Renal Disease; Renal Transplant
    Interventions
    Anti-Thymocyte Globulin; TOL101; TOL101; Steroids; Tacrolimus; Mycophenolate mofetil (MMF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2010-07
    Completion
    2013-06
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease; Renal Transplant
    InterventionAnti-Thymocyte Globulin; TOL101; TOL101; Steroids +2 more
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • A Study of the Effects of Single Dose Corticosteroids on Response to Allergens

    NCT00828061 · start 2009-02-04

    Registered record
    Registry ID
    NCT00828061
    Conditions
    Allergic Rhinitis
    Interventions
    Placebo; prednisone; prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-02-04
    Completion
    2009-05-21
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionPlacebo; prednisone; prednisone
    PhasePhase 1
    Registry statusCompleted

  • Polycystic Liver Disease in Kidney Transplant

    NCT00934791 · start 2009-02

    Registered record
    Registry ID
    NCT00934791
    Conditions
    Polycystic Liver Disease
    Interventions
    Tacrolimus; Sirolimus; Mycophenolate Mofetil; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2009-02
    Completion
    2012-12
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Liver Disease
    InterventionTacrolimus; Sirolimus; Mycophenolate Mofetil; Prednisone
    PhaseNot applicable
    Registry statusTerminated

  • A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma

    NCT00686335 · start 2008-06

    Registered record
    Registry ID
    NCT00686335
    Conditions
    Asthma
    Interventions
    Lodotra; Cortancyl
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-06
    Completion
    2010-05
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionLodotra; Cortancyl
    PhasePhase 2
    Registry statusCompleted

  • Rituximab in Patients With Relapsed or Refractory TTP-HUS

    NCT00531089 · start 2007-12

    Registered record
    Registry ID
    NCT00531089
    Conditions
    Thrombotic Thrombocytopenic Purpura; Hemolytic Uremic Syndrome
    Interventions
    Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2007-12
    Completion
    2011-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombotic Thrombocytopenic Purpura; Hemolytic Uremic Syndrome
    InterventionRituximab
    PhasePhase 2
    Registry statusUnknown

  • Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

    NCT00527124 · start 2007-11

    Registered record
    Registry ID
    NCT00527124
    Conditions
    Adenocarcinoma of the Prostate; Stage IV Prostate Cancer
    Interventions
    cediranib maleate; docetaxel; prednisone; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-11
    Completion
    2013-11
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate; Stage IV Prostate Cancer
    Interventioncediranib maleate; docetaxel; prednisone; laboratory biomarker analysis
    PhasePhase 2
    Registry statusTerminated

  • Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

    NCT00107198 · start 2006-03-10

    Registered record
    Registry ID
    NCT00107198
    Conditions
    Ann Arbor Stage I Childhood Hodgkin Lymphoma; Ann Arbor Stage II Childhood Hodgkin Lymphoma; Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
    Interventions
    Conventional Surgery; Cyclophosphamide; Doxorubicin Hydrochloride; Prednisone; Radiation Therapy; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-03-10
    Completion
    2026-03-31
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnn Arbor Stage I Childhood Hodgkin Lymphoma; Ann Arbor Stage II Childhood Hodgkin Lymphoma; Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
    InterventionConventional Surgery; Cyclophosphamide; Doxorubicin Hydrochloride; Prednisone +2 more
    PhasePhase 2
    Registry statusCompleted

  • GEM05 for Patients With Multiple Myeloma Under 65 Years

    NCT00461747 · start 2006-03

    Registered record
    Registry ID
    NCT00461747
    Conditions
    Multiple Myeloma
    Interventions
    VBMCP/VBAD/Velcade; Thalidomide/Dexamethasone; Velcade/Thalidomide/Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-03
    Completion
    2008-12
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionVBMCP/VBAD/Velcade; Thalidomide/Dexamethasone; Velcade/Thalidomide/Dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma

    NCT00774826 · start 2005-12

    Registered record
    Registry ID
    NCT00774826
    Conditions
    Follicular Lymphoma
    Interventions
    R-CVP; R-CHOP; R-FM
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2005-12
    Completion
    2014-03
    Enrolment
    534

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma
    InterventionR-CVP; R-CHOP; R-FM
    PhasePhase 3
    Registry statusUnknown

  • Withdrawal of Steroids, Cyclosporine A Dose Reduction and Switch to Mycophenolatmofetile After Heart Transplantation

    NCT00359658 · start 2004-11

    Registered record
    Registry ID
    NCT00359658
    Conditions
    Heart Transplantation
    Interventions
    prednisolon; Mycophenolatmofetile; Cyclosporin A
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-11
    Completion
    2008-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Transplantation
    Interventionprednisolon; Mycophenolatmofetile; Cyclosporin A
    PhaseNot applicable
    Registry statusCompleted

  • Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia

    NCT00458848 · start 2004-10

    Registered record
    Registry ID
    NCT00458848
    Conditions
    Leukemia
    Interventions
    asparaginase; daunorubicin hydrochloride; etoposide; idarubicin; imatinib mesylate; mercaptopurine; methotrexate; methylprednisolone; mitoxantrone hydrochloride; prednisone; vincristine sulfate; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-10
    Completion
    2014-03
    Enrolment
    470

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Interventionasparaginase; daunorubicin hydrochloride; etoposide; idarubicin +11 more
    PhasePhase 2
    Registry statusCompleted

  • Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)

    NCT00092989 · start 2004-07

    Registered record
    Registry ID
    NCT00092989
    Conditions
    Asthma
    Interventions
    montelukast sodium; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-07
    Completion
    2007-03
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    Interventionmontelukast sodium; placebo
    PhasePhase 3
    Registry statusCompleted